Výsledky vyhledávání - "Edward W. Greeno"

Akademický článek

RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long‐term survival and reveals a role for ANGPTL4

Autor: Marie K. Kirby, Ryne C. Ramaker, Jason Gertz, Nicholas S. Davis, Bobbi E. Johnston, Patsy G. Oliver, Katherine C. Sexton, Edward W. Greeno, John D. Christein, Martin J. Heslin, James A. Posey, William E. Grizzle, Selwyn M. Vickers, Donald J. Buchsbaum, Sara J. Cooper, Richard M. Myers

Publikováno v: Molecular Oncology, Vol 10, Iss 8, Pp 1169-1182 (2016)

Background Pancreatic adenocarcinoma patients have low survival rates due to late‐stage diagnosis and high rates of cancer recurrence even after surgical resection. It is important to understand the molecular characteristics associated with surviva

Externí odkaz: https://doaj.org/article/18b28309935b4450822c1557f59a1f5b

Zobrazit plný text záznamu

A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers

Autor: Daniel A. Saltzman, Lance B. Augustin, Thomas J. Gniadek, Gerald Batist, Edward W Greeno, Arnold S. Leonard, Janet L. Schottel

Publikováno v: Journal of Immunotherapy (Hagerstown, Md. : 1997)

Salmonella has been shown to preferentially colonize solid tumors. It is known that toxicity limits the systemic administration of immunomodulatory cytokines that have a significant anticancer effect. Therefore, we tested a unique cancer treatment st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd53458e70f3ad4603e88afa628772a4
https://doi.org/10.1097/cji.0000000000000325

Zobrazit plný text záznamu

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Autor: Herbert Hurwitz, Vaibhav Sahai, Chris Verslype, Jason Clark, Johanna C. Bendell, Ashwin Reddy Sama, Eric Van Cutsem, Manuel Hidalgo, Edward W Greeno, Eileen M. O'Reilly, Chung Pin Li, Kenneth H. Yu, Christopher James Walker, Fitzroy Dawkins, Teresa Macarulla, Marcelo Garrido Salvo

Publikováno v: Investigational New Drugs. 36:683-695

Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP]

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4efb9dd95fab56ab09c97a08030248f
https://doi.org/10.1007/s10637-018-0580-2

Zobrazit plný text záznamu

RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4

Autor: Katherine C. Sexton, Sara J. Cooper, Martin J. Heslin, Nicholas S. Davis, Donald J. Buchsbaum, Ryne C. Ramaker, James Posey, Edward W Greeno, John D. Christein, Patsy G. Oliver, Selwyn M. Vickers, Jason Gertz, William E. Grizzle, Marie K. Kirby, Bobbi E Johnston, Richard M. Myers

Publikováno v: Molecular Oncology. 10:1169-1182

Background Pancreatic adenocarcinoma patients have low survival rates due to late-stage diagnosis and high rates of cancer recurrence even after surgical resection. It is important to understand the molecular characteristics associated with survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5c7abd884206b5974031446224c9c44
https://doi.org/10.1016/j.molonc.2016.05.004

Zobrazit plný text záznamu

Provider perspective: The clinical value of a novel digital medicine program in gastrointestinal oncology

Autor: Paul Morales, Ellen Travis, Daniel Beiswenger, Edward W Greeno, R. Scooter Plowman, Xue Wang

Publikováno v: Journal of Clinical Oncology. 38:76-76

76 Background: The differences in colorectal cancer (CRC) treatment between infusion and oral chemotherapy have challenged clinical teams to maintain clinical quality and patient communications with self-administered therapies. The complexity of many

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff8b86a7606e6d385eeb227e1ff7a793
https://doi.org/10.1200/jco.2020.38.4_suppl.76

Zobrazit plný text záznamu

Neoadjuvant interferon‐based chemoradiation for borderline resectable and locally advanced pancreas cancer: a Phase II pilot study

Autor: Todd M Tuttle, Eric H. Jensen, Edward W Greeno, Leonard Armstrong, Selwyn M. Vickers, Chung K Lee, Timothy D. Sielaff

Publikováno v: HPB. 16(2):131-139

Objectives: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil, cisplatin, interferon-α and radiation) given in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caddf6e9a6c63e3dfa97747a8c68782f

Zobrazit plný text záznamu

Turning on the lights in gastrointestinal oncology: How digital medicines reveal clinical insights on medication adherence and patient behaviors

Autor: Edward W Greeno, Won Chan Lee, Daniel Beiswenger, Ellen Travis, Paul Morales

Publikováno v: Journal of Clinical Oncology. 37:e15118-e15118

e15118 Background: Oral therapies in colorectal cancer (CRC) introduce unique complexities in care. Understanding adherence in patients using capecitabine can be challenging. The Discover Program, a novel digital medicine program (DMP), was integrate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb9d6917930bd757cc66d9ff2c1a33d6
https://doi.org/10.1200/jco.2019.37.15_suppl.e15118

Zobrazit plný text záznamu

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours

Autor: James Fisher, Arkadiusz Z. Dudek, Mark N. Kirstein, Brent W. Williams, Vadim J. Gurvich, Jatinder K. Lamba, Robert A. Kratzke, Edward W Greeno, Richard C. Brundage, Keith M. Skubitz, Amit Khatri, Lev G Lis

Publikováno v: British Journal of Cancer

Background: Gemcitabine is used for the treatment of several solid tumours and exhibits high inter-individual pharmacokinetic variability. In this study, we explore possible predictive covariates on drug and metabolite disposition. Methods: Forty pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c784c8332ae81e7cbb26c446f17dc7fa
http://europepmc.org/articles/PMC3899768

Zobrazit plný text záznamu

Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031

Autor: Mace L. Rothenberg, Edward W Greeno, Eileen M. O'Reilly, Lalan S. Wilfong, Paul A. Decker, Mitchell C. Posner, Ross A. Abrams, Vincent J. Picozzi, W. Traverso, R. C. Martin, Peter W.T. Pisters

Publikováno v: Annals of Oncology. 22:348-354

Background: The American College of Surgeons Oncology Group sought to confirm the efficacy of a novel interferon-based chemoradiation regimen in a multicenter phase II trial. Patients and methods: Patients with resected (R0/R1) adenocarcinoma of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c36f3d4d84dfcc6f404a76bea76b7ce7
https://doi.org/10.1093/annonc/mdq384

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání